Houston-based GoCo.io has acquired a company that aims to improve the work-from-home employee experience. Courtesy of GoCo

A Houston software startup has made a strategic acquisition to account for the increasingly large number of companies employing a remote-first workforce.

After closing a $15 million series B funding round last year, GoCo.io, an HR solutions software platform, has acquired WFHomie, a platform that helps remote-first companies enhance the employee experience as well as keep up with people analytics. According to GoCo research, most HR professionals report that they are being asked to retain top talent — employee engagement programs are key to driving that retention, the company says in a news release.

“We know that employee experience is top of mind for SMBs and the HR teams that support them,” says Nir Leibovich, co-founder and CEO of GoCo, in the release. “Our team and our platform are growing rapidly in support of our mission to empower HR professionals, and this acquisition is a key step in that direction.

"It’s clear that the leadership of WFHomie share our vision, passion, and excitement for creating innovative products that help companies build better workplaces," he continues. "We’re confident that the WFHomie team will bring the expertise and agility we need to ship new products and expand our service offerings in line with that vision.”

The details of the transaction were not disclosed. The WFHomie team will be on boarded at GoCo.

Founded in November of 2020 in direct response to the pandemic, Toronto-based WFHomie raised $1.6 million in seed funding in 2021.

“Nir and the leadership team at GoCo are dedicated to building a future where HR and People Ops leaders have the bandwidth to support their employees effectively and create thriving, high-performing workplaces” says Pavla Bobosikova, co-founder and CEO of WFHomie in the news release. “We share the same vision – to improve work-life for employees, while empowering organizations to operate more effectively.”

Founded in 2015 by Leibovich, Jason Wang, and Michael Gugel, GoCo has raised $27.5 million to date and has over 100 employees, according to LinkedIn.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”